Editas Medicine patent interference narrows; USPTO reaffirms PTAB ruling favoring Broad Institute

Reuters03-27
<a href="https://laohu8.com/S/EDIT">Editas Medicine</a> patent interference narrows; USPTO reaffirms PTAB ruling favoring Broad Institute
  • The U.S. Patent and Trademark Office reaffirmed a Patent Trial and Appeal Board decision favoring the Broad Institute in a CRISPR/Cas9 patent interference involving CRISPR/Cas9 gene editing in human cells.
  • The dispute involves claims by the University of California, the University of Vienna, and Emmanuelle Charpentier against the Broad Institute, MIT, and Harvard.
  • The matter was on remand from the U.S. Court of Appeals for the Federal Circuit after a May 2025 decision that affirmed in part and vacated in part the PTAB’s prior decision.
  • The PTAB’s latest ruling is its third decision finding Broad was first to invent the use of CRISPR/Cas9 for gene editing in eukaryotic cells, including human cells.
  • The opposing parties retain the right to appeal the decision to the Federal Circuit.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270700PRIMZONEFULLFEED9679580) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment